Amgen Inc.: stockholders equity
Stockholders equity for Amgen Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Amgen Inc. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2006-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 8,658,000,000 | USD | 2026-02-13 | 10-K · 0000318154-26-000010 |
| At date | 2024-12-31 | 5,877,000,000 | USD | 2026-02-13 | 10-K · 0000318154-26-000010 |
| At date | 2023-12-31 | 6,232,000,000 | USD | 2026-02-13 | 10-K · 0000318154-26-000010 |
| At date | 2022-12-31 | 3,661,000,000 | USD | 2026-02-13 | 10-K · 0000318154-26-000010 |
| At date | 2021-12-31 | 6,700,000,000 | USD | 2025-02-14 | 10-K · 0000318154-25-000010 |
| At date | 2020-12-31 | 9,409,000,000 | USD | 2024-02-14 | 10-K · 0000318154-24-000011 |
| At date | 2019-12-31 | 9,673,000,000 | USD | 2023-02-09 | 10-K · 0000318154-23-000017 |
| At date | 2018-12-31 | 12,500,000,000 | USD | 2022-02-16 | 10-K · 0000318154-22-000010 |
| At date | 2017-12-31 | 25,241,000,000 | USD | 2021-02-09 | 10-K · 0000318154-21-000010 |
| At date | 2016-12-31 | 29,875,000,000 | USD | 2020-02-12 | 10-K · 0000318154-20-000017 |
| At date | 2015-12-31 | 28,083,000,000 | USD | 2019-02-13 | 10-K · 0000318154-19-000008 |
| At date | 2014-12-31 | 25,778,000,000 | USD | 2018-02-13 | 10-K · 0000318154-18-000004 |
| At date | 2013-12-31 | 22,096,000,000 | USD | 2017-02-14 | 10-K · 0000318154-17-000004 |
| At date | 2012-12-31 | 19,060,000,000 | USD | 2016-02-16 | 10-K · 0000318154-16-000031 |
| At date | 2011-12-31 | 19,029,000,000 | USD | 2015-02-19 | 10-K · 0000318154-15-000005 |
| At date | 2010-12-31 | 23,944,000,000 | USD | 2014-02-24 | 10-K · 0000318154-14-000004 |
| At date | 2009-12-31 | 22,667,000,000 | USD | 2013-02-27 | 10-K · 0001445305-13-000364 |
| At date | 2008-12-31 | 20,885,000,000 | USD | 2012-02-29 | 10-K · 0001193125-12-086670 |
| At date | 2007-12-31 | 18,512,000,000 | USD | 2011-02-25 | 10-K · 0000950123-11-018800 |
| At date | 2006-12-31 | 19,841,000,000 | USD | 2010-03-01 | 10-K · 0001193125-10-044311 |
Related financial histories
- Amgen Inc.: total assets
- Amgen Inc.: cash and cash equivalents
- Amgen Inc.: net income or loss
- Amgen Inc.: operating cash flow
- Amgen Inc.: capital expenditure payments
- Amgen Inc.: revenue
- Amgen Inc.: contract revenue excluding tax
- Amgen Inc.: financing cash flow
- Amgen Inc.: investing cash flow
- Amgen Inc.: retained earnings or deficit
- Amgen Inc.: basic weighted-average shares
- Amgen Inc.: diluted weighted-average shares
- Amgen Inc.: basic earnings per share
- Amgen Inc.: diluted earnings per share
- Amgen Inc.: income tax expense or benefit
- Amgen Inc.: net property, plant and equipment
- Amgen Inc.: share-based compensation expense
- Amgen Inc.: operating income or loss
- Amgen Inc.: current assets
- Amgen Inc.: current liabilities
- Amgen Inc.: current accounts payable
- Amgen Inc.: goodwill carrying amount
- Amgen Inc.: net finite-lived intangible assets
- Amgen Inc.: net current accounts receivable
- Amgen Inc.: common-stock repurchase payments
- Amgen Inc.: net inventory
- Amgen Inc.: selling, general and administrative expense
Inspect the source
- Entity
- Amgen Inc. / CIK 0000318154
- Captured
- 2026-09-19T14:56:36.959Z
- SEC response SHA-256
fdf5906752dbed7151b14f5e765db25e75393cedef4a2582d976623b49e2e4c7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000318154.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))